Micreos Raises Euro 30 Million for Endolysin Technology Set to Replace Antibiotics

PR78071

THE HAGUE, Netherlands, March 29, 2019 /PRNewswire=KYODO JBN/ --

Funding for clinical development program XZ.700 and Gladskin Eczema USA launch

Dutch biotechnology company Micreos announced it has secured Euro30 million in

funding to accelerate the development of its endolysin technology, set to

replace antibiotics. Proceeds are earmarked for the clinical development

program of its endolysin XZ.700 and the USA launch of its breakthrough OTC

Gladskin product for eczema.

According to the World Health Organization, antibiotic resistance is one of the

world's biggest health threats. The call for true alternatives is more pressing

than ever. Antibiotics do not distinguish between bad and good bacteria, and

their use induces resistance.

Endolysins have three distinct features: (1) ability to target only unwanted

bacteria while preserving the microbiome, which is essential for our health.

(2) ability to kill antibiotic resistant strains of bacteria (3) emergence of

resistance against endolysins is not expected.

Endolysin technology opens a new therapeutic window for treatment of chronic

inflammatory conditions, such as atopic dermatitis and persistent wound

infections, including those caused by MRSA.

Micreos' Staphefekt(TM) SA.100, is the world's first endolysin approved for

human use. It selectively targets Staphylococcus aureus - often referred to as

'Staph' - which is a major trigger of eczema and other inflammatory skin

conditions.

Video: how Staphefekt(TM)works in eczema: https://youtu.be/qxg2kxfFw6Q

"Since its introduction, Gladskin has helped over 100.000 people in Europe with

eczema, acne, and rosacea, many of them reporting a life-changing impact,''

remarked Skyler Stein, Head of Gladskin USA. "Gladskin is pioneering the use of

endolysins to rebalance the skin microbiome and improve skin health." Chosen as

Europe's Most Impactful Innovation 2018, Gladskin is now preparing its launch

in the United States.

The Euro30 million funding includes a non-dilutive Euro5.4 million Innovation

Credit granted by the Dutch Ministry of Economic Affairs. Micreos has conducted

several studies with Gladskin, including trials on eczema, acne and rosacea.

Studies in orphan indications with a high unmet need, like primary immune

deficiencies and Netherton disease are ongoing.

Micreos CEO Mark Offerhaus noted: "This funding from existing and new investors

will advance the adoption of our endolysin technology and help us reach the

millions who stand to benefit. We are exploring partnerships to further

accelerate the commercialization of our technology."

About Micreos

Micreos is a Dutch biotechnology company with production and R&D centers for

endolysins in Bilthoven and for phages in Wageningen. Micreos maintains a

long-term collaboration with ETH Zurich (Prof Loessner) in Switzerland and

numerous medical and technology centres, including Erasmus MC (Rotterdam), the

Public Health Lab Kennemerland, the Dutch Burn Centres (Beverwijk), Copenhagen

University and many others. Gladskin is a Micreos Human Health brand

(www.gladskin.com) for inflammatory skin conditions such as eczema,

inflammatory acne, psoriasis and rosacea. Phageguard is the Micreos Food Safety

brand for FDA- and USDA-approved phage products against Listeria, Salmonella

and E. coli (www.phageguard.com).

Websites: www.micreos.com, www.gladskin.com, www.phageguard.com

(Photo: https://mma.prnewswire.com/media/843302/Skyler_Headshot.jpg)

(Photo: https://mma.prnewswire.com/media/843301/Micreos_IdeasFromEurope.jpg)

(Photo: https://mma.prnewswire.com/media/843300/Gladskin_products_30_ml.jpg)

Source: Micreos